New insights into the mechanisms of action of radioimmunotherapy in lymphoma

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 8, 2008, Pages 987-998

  Ivanov, Andrei ^a   Swann, Ruth ^a   Illidge, Tim ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LL2 I 131; MONOCLONAL ANTIBODY LL2 Y 90; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY LYM 1 I 131; RADIOISOTOPE; RITUXIMAB; TOSITUMOMAB I 131;

ANEMIA; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER REGRESSION; DOSIMETRY; DRUG ELIMINATION; DRUG HALF LIFE; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LINEAR ENERGY TRANSFER; LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; DECISION TREES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 47949088118     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.8.0006     Document Type: Review

References (74)

1. Adams, G. P., Weiner, L. M. (2005) Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157
2. Anderson, D. R., Grillo-López, A., Varns, C., Chambers, K. S., Hanna, N. (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25: 705-708
3. Buchsbaum, D. J., Wahl, R. L., Glenn, S. D., Normolle, D. P., Kaminski, M. S. (1992) Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res. 52: 637-642
4. Chan, H. T., Hughes, D., French, R. R., Tutt, A. L., Walshe, C. A., Teeling, J. L., Glennie, M. J., Cragg, M. S. (2003) CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 63: 5480-5489
5. Clark, E. A., Shu, G. (1987) Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J. Immunol. 138: 720-725
6. Coiffier B. (2003) Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev. 17: 25-31
7. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., Gisselbrecht C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346: 235-242
8. Cragg, M. S., Glennie, M. J. (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103: 2738-2743
9. Cragg, M. S., Walshe, C. A., Ivanov, A. O., Glennie, M. J. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8: 140-174
10. Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Zelenetz, A., Wahl, R. L., Kroll, S., Coleman, M., Goris, M., Levy, R., Knox, S. J. (2004) The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer. Res. 10: 7792-7798
11. DeNardo, G. L., DeNardo, S. J., Goldstein, D. S., Kroger, L. A., Lamborn, K. R., Levy, N. B., McGahan, J. P., Salako, Q., Shen, S., Lewis, J. P. (1998) Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol. 16: 3246-3256
12. DeNardo, G. L., Kukis, D. L., Shen, S., DeNardo, D. A., Meares, C. F., DeNardo, S. J. (1999) 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin. Cancer Res. 5: 533-541
13. Du, Y., Honeychurch, J., Cragg, M. S., Bayne, M., Glennie, M. J., Johnson, P. W., Illidge, T. M. (2004) Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 103:1485-1494
14. Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., Kroll, S., Goldsmith, S. J., Coleman, M. (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 23:7565-7573
15. Gauld, S. B., Blair, D., Moss, C. A., Reid, S. D., Harnett, M. M. (2002) Differential roles for extracellularly regulated kinase-mitogen-activated protein kinase in B cell antigen receptor-induced apoptosis and CD40-mediated rescue of WEHI-231 immature B cells. J. Immunol. 168: 3855-3864
16. Goldenberg, D. M., Sharkey, R. M. (2005) Radioimmunotherapy of non-Hodgkin's lymphoma revisited. J. Nucl. Med. 46: 383-384.
17. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., Izon, D. O. (1991) Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol. 9: 548-564
18. Golding, S. E., Rosenberg, E., Neill, S., Dent, P., Povirk, L. F., Valerie, K. (2007) Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 67: 1046-1053
19. Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubtischek, A., Darif, M., Schilder, R. J., Wiseman, G., White, C. A. (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103: 4429-4431
20. Gregory, S. A., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Horning, S. J., Knox, S. J., Lister, T. A., Radford, J. A., Press, O. W., Kaminski, M. S. (2005) Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL). J. Clin. Oncol. ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement): 6561
21. Grillo-Lopez, A. J. (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev. Anticancer Ther. 2: 485-493
22. Grossbard, M. L., Press, O. W., Appelbaum, F. R., Bernstein, I. D., Nadler, L. M. (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80: 863-878
23. Hagan, M., Wang, L., Hanley, J. R., Park, J. S., Dent, P. (2000) Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat. Res. 153: 371-383
24. 90Y-ibritumomab tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 First-line Indolent Trial (FIT) in 414 patients Blood 110: 198a, Abstract 643
25. Hofmeister, J. K., Cooney, D., Coggeshall, K. M. (2000) Clustered CD20-induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26: 133-143
26. Holder, M., Grafton, G., MacDonald, I., Finney, M., Gordon, J. (1995) Engagement of CD20 suppresses apoptosis in germinal center B cells. Eur. J. Immunol. 25: 3160-3164
27. Hollmann, C. A., Owens, T., Nalbantoglu, J., Hudson, T. J., Sladek, R. (2006) Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. Cancer Res. 66: 3550-3557
28. Horning, S. J., Younes, A., Jain, V., Kroll, S., Lucas, J., Podoloff, D., Goris, M. (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 23: 712-719
29. Illidge, T. M., Johnson, P. W. (2000) The emerging role of radioimmunotherapy in haematological malignancies. Br. J. Haematol. 108: 679-688
30. Illidge, T. M., Cragg, M. S., McBride, H. M., French, R. R., Glennie, M. J. (1999) The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma. Blood 94: 233-243
31. Ivanov, A., Krysov, S., Cragg, M. S., Illidge, T. M. (2008) Radiation therapy combined with anti-CD20 antibody tositumomab initiates ERK/MAPK dependent cell death. Clin. Cancer Res. In press
32. Johnson, P., Glennie, M. (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 30: 3-8
33. Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, A. M., Hamacher, K. A., Ma, D., Humm, J. L., Brechbiel, M. W., Molinet, R., Scheinberg, D. A. (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100: 1233-1239
34. Kaminski, M. (2007) I131-tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 years. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 8033
35. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., Glenn, S. D, Wahl, R. L. (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329: 459-465
36. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., Wahl, R. L. (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14: 1974-1981
37. Kaminski, M, S,, Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., Vose, J. M. (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19: 3918-3928
38. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352: 441-449
39. Kansas, G. S., Tedder, T. F. (1991) Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J. Immunol. 147: 4094-4102
40. Knox, S. J., Meredith, R. F. (2000) Clinical radioimmunotherapy. Semin. Radiat. Oncol. 10: 73-93
41. Kolch, W. (2005) Coordinating ERK/MAPK signaling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6: 827-837
42. Koral, K. F., Dewaraja, Y., Li, J., Barrett, C. L., Regan, D. D., Zasadny, K. R., Rommelfanger, S. G., Francis, I. R., Kaminski, M. S., Wahl, R. L (2003a) Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J. Nucl. Med. 44: 457-464
43. Koral, K. F., Kaminski, M. S., Wahl, R. L. (2003b) Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med. 44:1541-1543
44. Lee, J. R., Koretzky, G. A. (1998) Extracellular signal-regulated kinase-2, but not c-Jun NH2-terminal kinase, activation correlates with surface IgM-mediated apoptosis in the WEHI 231 B cell line. J. Immunol. 161: 1637-1644
45. Leveille, C., Al-Daccak, R., Mourad, W. (1999) CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur. J. Immunol. 29: 65-74
46. Link, B., Kaminski, M. S., Coleman, M. (2004) Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin lymphoma. Proc. ASCO 23: Abstract No. 6520
47. Lyng, F. M., Maguire, P., McClean, B., Seymour, C., Mothersill, C. (2006) The involvement of calcium and MAP kinase signaling pathways in the production of radiation-induced bystander effects. Radiat Res. 165: 400-409
48. Mathas, S., Rickers, A., Bommert, K., Dörken, B., Mapara, M. Y. (2000) Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 60: 7170-7176
49. McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., Scheinberg, D. A. (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25: 1341-1351
50. Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P. L., Rule, S., Liberati, A. M., Milpied, N., Hess, G., Stein, H., Kalmus, J., Marcus, R. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110: 54-58
51. Nadler, L. M., Ritz, J., Hardy, R., Pesando, J. M., Schlossman, S. F., Stashenko, P. (1981) A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 67: 134-140
52. O'Keefe, T. L., Williams, G. T., Davies, S. L., Neuberger, M. S. (1998) Mice carrying a CD20 gene disruption. Immunogenetics 48: 125-132
53. Park, S. I., Press, O. W. (2007) Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr. Opin. Hematol. 14: 632-638
54. Postema, E. J. (2004) Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma. J. Nucl. Med. 45: 2126-2127
55. Press, O. W., Rasey, J. (2000) Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol. 27: 62-73
56. Press, O. W., Farr, A. G., Borroz, K. I., Anderson, S. K., Martin, P. J. (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 49: 4906-4912
57. Press, O. W., Shan, D., Howell-Clark, J., Eary, J., Appelbaum, F. R., Matthews, D., King, D. J., Haines, A. M., Hamann, P., Hinman, L., Shochat, D., Bernstein, I. D. (1996) Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56: 2123-2129
58. Robak, T. (2004) Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk. Lymphoma 45: 205-219
59. Shan, D., Ledbetter, J. A., Press, O. W. (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652
60. Sharkey, R. M., Goldenberg, D. M. (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46: 115S-127S
61. Sharkey, R. M., Behr, T. M., Mattes, M. J., Stein, R., Griffiths, G. L., Shih, L. B, Hansen, H. J., Blumenthal, R. D., Dunn, R. M., Juweid, M. E., Goldenberg, D. M. (1997) Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 44: 179-188
62. Smeland, E. B., Beiske, K., Ek, B., Watt, R., Pfeifer-Ohlsson, S., Blomhoff, H. K., Godal, T., Ohlsson, R. (1987) Regulation of c-myc transcription and protein expression during activation of normal human B cells. Exp. Cell Res. 172: 101-109
63. Sutherland, C. L., Heath, A. W., Pelech, S. L., Young, P. R., Gold, M. R. (1996) Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. 157: 3381-3390
64. Tedder, T. F., Engel, P. (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15: 450-454
65. Tedder, T. F., Forsgren, A., Boyd, A. W., Nadler, L. M., Schlossman, S. F. (1986) Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur. J. Immunol. 16: 881-887
66. Uchida, J., Lee, Y., Hasegawa, M., Liang, Y., Bradney, A., Oliver, J. A., Bowen, K., Steeber, D. A., Haas, K. M., Poe, J. C., Tedder, T. F. (2004) Mouse CD20 expression and function. Int. Immunol. 16: 119-129
67. Wahl, R. L. (2003) The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin. Oncol. 30: 31-38
68. Wilder, R. B., DeNardo, G. L., DeNardo, S. J. (1996) Radioimmunotherapy: recent results and future directions. J. Clin. Oncol. 14: 1383-1400
69. Winter, J. N., Gascoyne, R. D., Van Besien, K. (2004) Low-grade lymphoma. Hematology (Am Soc Hematol Educ Program), 2004: pp 203-220
70. Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., Spies, S., Bartlett, N. L., Schilder, R. J., Murray, J. L., Saleh, M., Allen, R. S., Grillo-López, A. J., White, C. A. (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99: 4336-4342
71. Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J, Spies, S., Silverman, D. H., Parker, E., Grillo-López, A. J. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17: 3793-3803
72. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., White, C. A. (2002a) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20: 3262-3269
73. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-López, A. J., Multani, P., White, C. A. (2002b) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20: 2453-2463
74. Witzig, T. E., White, C. A., Gordon, L. I., Wiseman, G. A., Emmanouilides, C., Murray, J. L., Lister, J., Multani, P. S. (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J. Clin. Oncol. 21: 1263-1270